KBI Biopharma, Inc. is a global contract development and manufacturing organization (CDMO) that provides integrated drug development and biomanufacturing services to life science companies. Headquartered in Durham, North Carolina, the company operates facilities globally, offering a broad suite of capabilities from cell line development through clinical and commercial manufacturing. Its technical expertise spans mammalian and microbial expression systems, process and analytical development, formulation, and characterization.
The company's service portfolio is supported by two proprietary technology platforms: SUREtechnology for mammalian systems and PUREplatform for microbial expression systems. These platforms are central to its offerings in biopharmaceutical development and manufacturing. KBI Biopharma serves the biologics development and manufacturing sectors within the broader life sciences industry.
KBI Biopharma has received industry recognition for its work, including top honors in the 2025 CDMO Leadership Awards. The company is characterized by its operational focus on accelerated development timelines and deep scientific expertise in biologics production.
